[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-survivors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-survivors":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,39,71,99,123,144,157,181,206,229,262,290,318,346,374,394,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100054116","assessing-the-effect-of-an-aerobic-exercise-program-on-vascular-function-in-women-with-non-metastatic-breast-cancer-100054116",false,"NCT07517224","Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer","Inclusion criteria:\n\n1. Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapies.\n2. Able to begin aerobic exercise within 4 weeks of the final chemotherapy cycle.\n3. Sedentary by self-reporting inactivity (\\\u003C90 min of moderate or vigorous exercise per week)\n4. Weight ≤154 kg\n5. Willing to complete all study activities\n6. Able to safely participate in moderate aerobic exercise.\n\nExclusion criteria:\n\n1. Current pregnant and lactating patients. Must have completed lactation prior to study start.\n2. Metastatic disease.\n3. Diagnosed cardiovascular disease prior to the initiation of chemotherapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.\n4. History of prior chemotherapy received for other cancer diagnosis.\n5. Non-English speaking","FEMALE","18 Years","70 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors.\n\nThe main questions it aims to answer are:\n\n* Is an 8-week aerobic exercise program feasible in breast cancer survivors after the completion of chemotherapy?\n* Is this 8-week aerobic exercise program beneficial for vascular function in breast cancer survivors?\n\nParticipants will:\n\n* Begin an 8-week aerobic exercise program, three days per week, after the completion of chemotherapy.\n* Visit our facility three times before the exercise program, 1 month after, and after the completion of the program.\n* Complete questionnaires, physical functional tests, and body composition and vascular measurements at every visit.",[26],"Breast Cancer Survivors","NOT_YET_RECRUITING","2026-07-09",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-08-01",{"date":35,"type":20},"2035-05-01",{"name":37,"class":38},"Loyola University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100639326","polarized-light-therapy-for-radiation-dermatitis-in-breast-cancer-100639326","NCT07600957","Polarized Light Therapy for Radiation Dermatitis in Breast Cancer","Efficacy of Polarized Polychromatic Light Therapy on Acute Radiation Dermatitis in Breast Cancer Patients: A Randomized Controlled Trial","PLARD-BREAST","Inclusion Criteria:\n\n1. Female patients aged 35-55 years.\n2. Histologically confirmed primary unilateral breast cancer.\n3. Status post breast-conserving surgery (lumpectomy).\n4. Planned for hypo fractionated whole-breast irradiation (HFWBI).\n5. Scheduled to receive a total radiation dose of 40-42.5 Gy delivered in 15-16 fractions over approximately 3 weeks.\n6. Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Previous radiotherapy to the same breast or thoracic region.\n2. Bilateral breast cancer.\n3. Metastatic or advanced systemic disease.\n4. Prior mastectomy.\n5. Active skin infection in the irradiated area.\n6. Pre-existing dermatologic disorders affecting the breast skin (e.g., eczema, psoriasis, dermatitis).\n7. Concurrent chemotherapy during radiotherapy.\n8. Presence of cardiac pacemaker or implantable electronic device in the treatment field.\n9. Open wounds or ulceration in the irradiated breast region.\n10. Any medical condition judged by the investigator to interfere with study participation or outcome assessment.","35 Years","55 Years",{"count":50,"type":20},60,[23],"This assessor-blinded randomized controlled trial aims to evaluate the efficacy of polarized polychromatic non-coherent light therapy as an adjunct to standard skin care in reducing acute radiation dermatitis in women with breast cancer undergoing hypofractionated whole-breast radiotherapy. Participants will be randomly allocated to receive either standard skin care alone or standard care combined with polarized light therapy initiated from the first radiotherapy session. Outcomes will include objective ultrasound-based dermal thickness measurements, clinical severity of radiation dermatitis using Radiation Therapy Oncology Group (RTOG) criteria.",[54,55,26],"Radio Dermatitis","Polarized Light",[57,58,59,60],"hypo fractionated whole-breast irradiation","radiodermatitis","polarized light therapy","ultrasound scan","RECRUITING","2026-05-21",{"date":64,"type":31},"2026-05-26",{"date":62,"type":31},{"date":67,"type":20},"2027-01-31",{"name":69,"class":38},"Beni-Suef University",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100541783","a-study-of-changes-in-thinking-related-to-aging-and-cancer-in-breast-cancer-survivors-trac-100541783","NCT06334354","A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)","Cognitive Aging in Older Long-term Breast Cancer Survivors","TRAC","Inclusion Criteria:\n\nAll Participants:\n\n* Per medical record and\u002For self-report, identifies as female\n* Per medical record and\u002For self-report, currently age 60-80\n* Per self-report, has access to a computer and internet connectivity\n* Score of \\\u003C11 on Blessed Orientation-Memory-Concentration Test (BOMC)\n* As per medical record or self-report, if currently taking psychoactive medications (including but not limited to antidepressants and anxiolytics), dose must have been stable at least two months prior to enrollment.\n* English fluent (as per self-report, fluency of \"well\" or \"very well\", and having a reasonable comprehension of the study conversation in the opinion of the research staff)\\*\\*\n\nBreast Cancer Survivors:\n\n* Per medical record and\u002For self-report, history of stage 0-3 breast cancer diagnosed between 50-60 years of age\n* Per medical record and\u002For self-report, no evidence of disease (NED)\n\nNon-Cancer Controls:\n\n* Per self-report, no history of breast cancer\n\n  * Language verification: For both survivors and controls, prior to enrollment, all will be asked the following two questions by a CRC to verify English fluency necessary for participation in the study:\n\n    1. How well do you speak English? (must respond \"Well\" or \"Very well\" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)\n    2. What is your preferred language for healthcare? (must respond English)\n\nExclusion Criteria:\n\nAll participants:\n\n* As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.)\n* As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation\n* As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder.\n* As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids)\n* As per medical record or self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for lupus.\n* As per medical record or self-report, participation in a conflicting (overlapping neurocognitive assessments) research study (i.e. MSK 18-294)\n\nBreast Cancer Survivors:\n\n* As per medical record or self-report, history of cancer recurrence\n* As per medical record or self-report, any history of another cancer except nonmelanoma skin cancer or first breast cancer (a secondary breast cancer is exclusionary)\n* As per medical record or self-report, breast cancer only treated with surgery\n\nNon-Cancer Controls:\n\n* As per medical record or self-report, history of treatment using radiation, chemotherapy, and\u002For Tamoxifen or Aromatase-inhibitors\n* As per medical record or self-report, any history of cancer except non-melanoma skin cancer",true,"60 Years","80 Years",{"count":83,"type":20},420,"OBSERVATIONAL","The purpose of this study is to look at how differences in cognitive (mental) function develop over time in breast cancer survivors compared to volunteers without a history of cancer (healthy volunteers). Both cancer survivors and healthy volunteers (who are the same age as the cancer survivors) will participate in this study so the researchers can compare the results of neurocognitive testing (which looks at memory, attention, and information processing) on each group of participants.",[26],[88],"Cognitive aging","2026-05-13",{"date":91,"type":31},"2026-05-14",{"date":93,"type":31},"2024-05-10",{"date":95,"type":20},"2028-08-31",{"name":97,"class":38},"Memorial Sloan Kettering Cancer Center",7,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":79,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":70},"100626732","tumour-cell-response-to-acute-aerobic-exercise-in-breast-cancer-survivors-modulatory-effects-of-exercise-type-and-intensity-100626732","NCT07439458","Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity","Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity (TCReX) No: RSU\u002FLSPA-PA-2024\u002F1-0004 is Financed by the Investment of the European Union Recovery and Resilience Facility and the State Budget Within the Project \"RSU Internal and RSU With LASE External Consolidation\" No. 5.2.1.1.i.0\u002F2\u002F24\u002FI\u002FCFLA\u002F005.","TCReX","Inclusion Criteria (intervention group):\n\n* Reproductive age (premenopausal);\n* Diagnosis of Stage II-III Triple-Negative Breast Cancer (TNBC) (negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2));\n* Timeframe of 3 to 9 months after completion of surgery, adjuvant chemotherapy, radiation therapy, and\u002For immunotherapy;\n* Physician-certified (cardiologist) physical fitness for exercise testing, supported by echocardiography (ECHO).\n\nInclusion Criteria (control group):\n\n* Reproductive age (premenopausal);\n* No current or prior diagnosis of any type of cancer;\n* Matched by age, body constitution, and physical fitness to the breast cancer participant group.\n\nExclusion Criteria:\n\n* Pregnancy;\n* Autoimmune diseases (e.g., thyroiditis, inflammatory bowel disease, atopic dermatitis, etc.);\n* Endocrine disorders (e.g., metabolic syndrome, diabetes);\n* Cardiovascular diseases;\n* Diagnosis of any other type of oncological disease;\n* Any condition for which physical activity is contraindicated (e.g., asthma, COPD, spinal disc herniation, severe iron deficiency anemia).",{"count":19,"type":20},[23],"Cancer has emerged as a prominent cause of mortality in the 21st century, with breast cancer (BC) being the most diagnosed malignancy. Multidisciplinary cancer management has improved survival chances, but side effects and long-term consequences of treatments have significant implications for cancer survivors' health-related quality of life. Exercise is increasingly considered and used in cancer treatment and follow-up. However, studies demonstrating the biological mechanisms underlying the anticarcinogenic effects (ACE) of exercise are insufficient to justify the most appropriate physical activity for different clinical scenarios. Achieving scientific excellence in understanding the ACE of exercise in cancer management is critical to optimize treatment and enhance patients' quality of life.",[111,112,26,113,114],"Acute Exercise","Breast Cancer Cell Lines","Healthy Women","Myokine Response","2026-05-11",{"date":91,"type":31},{"date":118,"type":31},"2024-04-01",{"date":120,"type":20},"2026-09-30",{"name":122,"class":38},"Riga Stradins University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":79,"sex":15,"minAge":16,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":70},"100640750","cognitive-impairment-assessment-in-breast-cancer-survivors-100640750","NCT07582770","Cognitive Impairment Assessment in Breast Cancer Survivors","Validation of Neuropsychological Tests for the Assessment of Cognitive Impairment in Breast Cancer Survivors","Inclusion Criteria:\n\n* Age between 18 and 65 years old\n* Patient with a previous documented diagnosis of non-metastatic breast cancer (only for breast cancer survivor gruop)\n* Patient has completed chemotherapy for at least 6 months and for a maximum of 36 months if planned (only for breast cancer survivor gruop)\n* Understanding of the Italian language and ability to give informed consent\n\nExclusion Criteria:\n\n* Presence of brain metastases or history of brain radiation therapy (only for breast cancer survivor gruop)\n* Patient with previous diagnosis of other malignant tumors in addition to breast cancer (only for breast cancer survivor gruop)\n* Patient with a previous diagnosis of malignant carcinomas (only for control gruop)\n* Patient with a history of brain damage with unresolved neurological consequences\n* Patient with previous or current serious neurological pathologies\n* Patient with severe psychiatric conditions\n* Patient with systemic pathologies that could interfere with cognitive abilities\n* Patient taking medications that have a strong cognitive impact and that have not been stabilized for at least 4 weeks prior to enrollment\n* Patient with visual or hearing impairments that are not properly corrected\n* Patient with any disability that might compromise the validity of cognitive tests","65 Years",{"count":132,"type":20},200,"This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test battery for the detection of cancer-related cognitive impairment in breast cancer survivors.",[135,26],"Cancer Related Cognitive Impairment","2026-05-06",{"date":89,"type":31},{"date":139,"type":20},"2026-05",{"date":141,"type":20},"2030-04",{"name":143,"class":38},"European Institute of Oncology",{"id":145,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":148,"briefSummary":24,"conditions":149,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":4},"100632710","Inclusion Criteria:\n\n1. Women (18+ years) with a stage I-III breast cancer diagnosis who have completed chemotherapies.\n2. Completed the final chemotherapy cycle within the past 4 weeks.\n3. Sedentary by self-reporting inactivity (\\\u003C90 min of moderate or vigorous exercise per week)\n4. Body mass index ≤40 kg\u002Fm²\n5. Willing to complete all study activities\n6. Able to safely participate in moderate aerobic exercise.\n\nExclusion Criteria:\n\n1. Current pregnant and lactating patients. Must have completed lactation prior to study start.\n2. Metastatic disease.\n3. Diagnosed cardiovascular disease prior to the initiation of chemotherapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.\n4. History of prior chemotherapy received for other cancer diagnosis.\n5. Non-English speaking",{"count":19,"type":20},[23],[26],"2026-04-03",{"date":152,"type":31},"2026-04-08",{"date":154,"type":20},"2026-05-01",{"date":35,"type":20},{"name":37,"class":38},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100630689","electroacupuncture-vs-auricular-acupressure-vs-waitlist-control-for-breast-cancer-endocrine-therapy-related-joint-pain-100630689","NCT07490938","Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain","Electroacupuncture Versus Auricular Acupressure Versus WaitliSt Control for Endocrine Therapy-related Joint Pain in Patients With Breast Cancer (EASE): A Pragmatic Multicenter Randomised Controlled Trial","EASE","Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer, stage I-IV, according to the AJCC Cancer Staging Manual (8th edition);\n* Aged 18-75 years;\n* Experiencing joint pain attributed to endocrine therapy, including localized or generalized joint pain, with symptoms persisting for at least 1 week;\n* Completion of all planned surgeries, chemotherapy, and radiotherapy, with a scheduled continuation of endocrine therapy for at least 1 additional year;\n* Self-reported worst joint pain score of ≥3 on a 0-10 Visual Analogue Scale (VAS) during the past week;\n* Life expectancy ≥1 year;\n* Voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n* Bone metastases involving the same site as the affected joint attributed to endocrine therapy;\n* History of fracture or surgery involving the affected joints within the past 6 months;\n* Implanted electronic medical devices;\n* Not suitable for acupuncture, including but not limited to bleeding tendencies (e.g. coagulation disorders or purpura) or local skin lesions at the intended acupoint sites.","75 Years",{"count":132,"type":20},[23],"The purpose of this pragmatic, multicenter, randomized controlled trial is to evaluate the clinical effectiveness and safety of electroacupuncture and auricular acupressure for improving joint pain related to endocrine therapy in breast cancer patients. A total of 200 participants will be recruited and randomly assigned to one of three groups: the Electroacupuncture Group (n=80), the Auricular Acupressure Group (n=80), or the Waitlist Control Group (n=40), using a central stratified block randomization method.\n\nThe primary objective is to compare changes in Worst Pain Item score among the three groups from baseline to the end of the treatment period, as measured by the Brief Pain Inventory-Short Form (BPI-SF). Secondary objectives include assessing pain interference, overall health status through the PROMIS scale, and quality of life specifically related to endocrine therapy using the FACT-ES. Additionally, the study will evaluate analgesic medication use (QAQ), patient expectations (Acupuncture Expectancy Scale), treatment adherence, and the occurrence of adverse events. By comparing these interventions, this study aims to generate high-quality evidence for the management of treatment-related arthralgia in breast cancer survivors.",[26,170],"Endocrine Therapy-Induced Joint Pain","2026-03-31",{"date":173,"type":31},"2026-04-06",{"date":175,"type":20},"2026-04",{"date":177,"type":20},"2027-12",{"name":179,"class":38},"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine",4,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":70},"100631387","tavns-for-breast-cancer-pain-and-symptom-management-100631387","NCT07500012","taVNS for Breast Cancer Pain and Symptom Management","Home-based Pain and Symptom Management for Breast Cancer Survivors: a Triple- Blinded RCT Pilot Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","Inclusion Criteria:\n\n1. are aged 18-79 years older;\n2. have histologically confirmed Stage 0, I, II, or III breast cancer;\n3. had completed their primary cancer treatment (surgery, radiotherapy, chemotherapy) and are currently on a stable survivorship care plan (e.g., endocrine therapy, supportive care), with no major treatment changes expected during the study;\n4. have experienced pain with a severity of 4 or greater out of 10 for at least ten days in the last month;\n5. are committed to maintaining the current treatment plan (e.g., endocrine therapy, supportive care) during the study;\n6. have reliable internet access;\n7. are willing to provide stool samples and undergo fNIRS brain imaging procedures;\n8. are able to read and understand English and provide written informed consent.\n\nExclusion Criteria:\n\n1. have metastatic breast cancer (Stage IV);\n2. have a current diagnosis of another active cancer;\n3. have a history of significant cardiac conditions, such as bradycardia, arrhythmia, recent myocardial infarction, or heart failure;\n4. have been diagnosed with a severe psychiatric illness (e.g., schizophrenia, bipolar I disorder with active psychosis) that could interfere with adherence to study procedures;\n5. have active inflammatory or malabsorptive gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis, celiac disease) that could confound gut microbiota results;\n6. have taken antibiotics, probiotics, or gastrointestinal motility agents (e.g., laxatives, prokinetics) within the past 3 months, due to potential disruption of gut microbiota;\n7. have a progressive neurological condition (e.g., Parkinson's disease, epilepsy, multiple sclerosis) that may impact fNIRS data quality or study participation;\n8. have a history of surgical or pharmacological vagotomy or are currently receiving implanted vagus nerve stimulation therapy, because of potential interference with autonomic regulation and taVNS mechanisms;\n9. have an active electronic or metallic implant (e.g., cochlear implant, pacemaker, neurostimulator) or other electronic\u002Fmetallic device in the head or neck area, which may be contraindicated for taVNS;\n10. are pregnant, breastfeeding, or planning to become pregnant during the study period;\n11. have had a recent initiation or dose change of pain medications (e.g., opioids, neuropathic agents) within the past 4 weeks.","79 Years",{"count":19,"type":20},[23],"1. To evaluate the feasibility and acceptability of a home-based taVNS intervention and follow-up for pain and symptom management in breast cancer survivors.\n2. To investigate the impact of taVNS on secondary outcomes, including pain, anxiety, depression, fatigue, and the brain-gut axis (BGA) in breast cancer survivors.",[26],[194,195,196],"pain","symptoms","transcutaneous auricular vagus nerve stimulation (taVNS)","2026-03-25",{"date":199,"type":31},"2026-03-30",{"date":201,"type":31},"2026-02-24",{"date":203,"type":20},"2028-02",{"name":205,"class":38},"Florida State University",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":70},"100631316","together-breast-cancer-support-platform-100631316","NCT07499089","Together-Breast Cancer Support Platform","\"Together\": A Bilingual Online Platform Support Intervention Project for Korean Breast Cancer Survivors","Together","Inclusion Criteria:\n\nMentors:\n\n* Age ≥ 18 years\n* Self-identify as Korean\n* Able to read, write, and speak both Korean and English\n* Diagnosed with breast cancer ≥ 2 years prior to enrollment\n* Completed active treatment or currently on long-term maintenance therapy\n* Access to a smartphone, computer, or similar device compatible with the study platform\n* Willing to participate for at least 3 months\n* Willing to complete required training and surveys\n\nMentees:\n\n* Age ≥ 18 years\n* Self-identify as Korean\n* Able to read, write, and speak Korean\n* Diagnosed with breast cancer\n* Currently receiving treatment (e.g., chemotherapy, radiation therapy, recent surgery, or endocrine therapy)\n* Access to a smartphone, computer, or similar device compatible with the study platform\n* Willing to participate for at least 3 months\n* Willing to complete required surveys\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria\n* Individuals unable to use the online platform or required technology\n* Individuals deemed non-compliant or inappropriate for participation based on investigator judgment (e.g., inability to complete study procedures)\n* Mentees diagnosed with ductal carcinoma in situ (DCIS)",{"count":215,"type":20},24,"The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. The main questions it aims to answer are: 1) Is the peer-support program acceptable and sustainable in terms of engagement between mentors and mentees over a 12-week period? 2) Does participation in the program improve quality of life, psychological well-being (including anxiety and depression), and perceived social support?\n\nParticipants will include Korean speaking breast cancer survivors (mentors) and patients currently undergoing treatment (mentees). After enrollment and matching based on screening information, participants will engage in peer-support interactions through an online platform for 12 weeks. Surveys will be administered at baseline, mid-point, post-intervention, and optional 6-month follow-up to assess outcomes.",[218,26],"Breast Cancer",[220],"Breast Cancer Survivorship, Korean American, Online peer support,","2026-03-24",{"date":199,"type":31},{"date":224,"type":20},"2026-04-01",{"date":226,"type":20},"2027-12-31",{"name":228,"class":38},"Cedars-Sinai Medical Center",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":237,"targetDuration":239,"studyType":84,"phases":4,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":70},"100622153","real-life-evaluation-of-endopredict-in-early-hrher2--breast-cancer-100622153","NCT07379918","Real-life Evaluation of Endopredict® in Early HR+\u002FHER2- Breast Cancer","French Prospective Real-life Evaluation of the Endopredict® Genomic Signature for HR-positive,HER2-negative Early Breast Cancer","SiMoSein","Inclusion Criteria:\n\n* Patient with early breast cancer, hormone receptor-positive, HER2 non-amplified, for whom clinical criteria are deemed insufficient to determine the need for adjuvant chemotherapy, combined with hormone therapy, after breast surgery.\n\nExclusion Criteria:\n\n* Patients who did not undergo testing or whose test results were not validated",{"count":238,"type":20},1000,"10 Years","EndoPredict is a genomic signature used to determine the 10-year risk of recurrence in early HR+\u002FHER2- breast cancers classified as of intermediate risk according to conventional clinical and pathological criteria, and to guide the adjuvant treatment decision: hormone therapy alone or hormone therapy and chemotherapy.\n\nSince 2016, french laboratories performing the Endopredict test, included prospectively analyzed tumors in the SiMoSein registry with data collection : age, tumor size, lymph node status, histology, grade, HR and HER2 IHC status, Ki67, EPscore, Epclin score, risk of relapse, absolue benefit from chemotherapy, risk of late relapse\n\nThe main objectives of the trial are to:\n\nEvaluate long-term relapse-free survival and overall survival over a 10-year period in breast cancer patients who underwent EndoPredict® testing according to:\n\n* EPclin risk class (low vs. high),\n* Lymph node status (N0\u002FN1),\n* Tumor size (pT),\n* Age groups (\\\u003C40 years, 40-49 years, 50-69 years, ≥70 years),\n* EP score alone.\n\nThis study provide real-life data to determine the clinical usefulness of this molecular signature in the management of early HR+\u002FHER2- breast cancers. The ultimate goal is to be able to offer therapeutic de-escalation (avoiding chemotherapy) to patients who are reliably assessed as having a low risk of relapse.",[242,26,243,244,245],"Breast Cancer (Early Breast Cancer)","Breast Cancer Prognostic","Early Hormone Receptor-positive (HR-positive)","HER2-negative Breast Cancer",[247,248,249,250,251,252],"breast cancer","early breast cancer","EndoPredict test","survival","HR positive","HER2 negative","2026-03-12",{"date":255,"type":31},"2026-03-13",{"date":257,"type":20},"2026-06-28",{"date":259,"type":20},"2031-06-28",{"name":261,"class":38},"Assistance Publique - Hôpitaux de Paris",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":15,"minAge":269,"maxAge":80,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":271,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":288,"locationsCount":70},"100618669","impact-of-pilates-exercises-on-bone-mineral-density-in-breast-cancer-survivors-receiving-hormonal-therapy-100618669","NCT07334626","Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy","PilatesBCS2026","Inclusion Criteria:\n\n1. Female breast cancer survivors aged 40-60 years.\n2. Histologically confirmed stage I-III breast cancer.\n3. Currently receiving hormonal therapy (aromatase inhibitors) for at least 3 months.\n4. At risk of osteoporosis or with low bone mineral density (BMD) defined by T-score ≤ -1.0 at lumbar spine or hip.\n5. Medically cleared for exercise, specifically low-to-moderate intensity Pilates.\n6. Able to attend supervised exercise sessions three times per week for 12 weeks.\n7. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Metastatic (stage IV) or recurrent breast cancer.\n2. History of osteoporotic fractures in the past 12 months.\n3. Severe cardiovascular, respiratory, or musculoskeletal conditions that contraindicate exercise.\n4. Uncontrolled hypertension, diabetes, or thyroid disorders.\n5. Current use of corticosteroids.\n6. Active bone metabolic disease other than osteoporosis (e.g., Paget's disease, osteomalacia).\n7. Severe cognitive impairment or psychiatric illness preventing adherence to exercise or supplementation.\n8. Known allergy or intolerance to calcium or vitamin D supplementation.\n9. Participation in another clinical trial with structured exercise or bone-targeted intervention within the last 3 months.","40 Years",{"count":50,"type":20},[23],"Breast cancer survivors receiving endocrine (hormonal) therapy (aromatase inhibitors) are at high risk for cancer treatment-induced bone loss and osteoporosis due to estrogen depletion.",[218,26,274,275,276],"Aromatase Inhibitors","Osteoporosis or Osteopenia","Pilates Exercise",[278,279,280,281],"pilates exercises","breast cancer survivors","bone mineral denisty","aromatase inhibitors","2026-01-14",{"date":284,"type":31},"2026-01-15",{"date":286,"type":31},"2026-01-01",{"date":120,"type":20},{"name":289,"class":38},"Benha University",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":130,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":70},"100614779","psychoeducation-and-well-being-after-breast-cancer-100614779","NCT07284030","Psychoeducation and Well-Being After Breast Cancer","The Effect of a Web-Based Supportive Psychoeducation Program on Psychological Well-Being, Quality of Life and Fear of Recurrence Applied to Patients Who Completed Active Breast Cancer Treatment","Psychoeducatio","Inclusion Criteria:\n\n* Female breast cancer survivors\n* Completed active breast cancer treatment (surgery, chemotherapy, radiotherapy) at least 12 months ago\n* Currently in remission (no evidence of active disease)\n* Age between 18-65 years\n* Able to read and write Turkish\n* Access to computer or smartphone with internet connection\n* Able to participate in online video sessions via Zoom\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Current cancer recurrence or metastatic disease\n* Active psychiatric disorder requiring treatment\n* Cognitive impairment that prevents participation in online sessions\n* Currently receiving active cancer treatment (excluding hormonal therapy)\n* Participation in another psychosocial intervention study\n* No internet access or inability to use web-based platforms\n* Male breast cancer patients\n* Unable to commit to 6-week program schedule",{"count":299,"type":20},72,[23],"This randomized controlled trial evaluates the effectiveness of a web-based psychoeducation program on psychological well-being and quality of life in breast cancer survivors who completed active treatment at least one year earlier.\n\nSeventy-two women will be randomly assigned to either a 6-week online psychoeducation program plus standard care or standard care alone. The intervention consists of weekly 30-45 minute online sessions focusing on coping strategies, psychosocial adjustment, quality of life, and psychological well-being.\n\nPrimary outcomes include psychological well-being, fear of cancer recurrence, quality of life, and hopelessness, assessed at baseline, post-intervention, and 2-month follow-up.",[218,26,303,304],"Breast - Female","Psycho-Oncology",[306,307,308],"Breast cancer","Psychoeducation","Web-based intervention","2025-12-14",{"date":311,"type":31},"2025-12-16",{"date":313,"type":31},"2025-05-01",{"date":315,"type":20},"2026-02-01",{"name":317,"class":38},"Yasemin Nazli",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":325,"minAge":16,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":70},"100614480","the-development-of-masld-among-survivors-of-breast-or-colorectal-cancer-100614480","NCT07280143","The Development of MASLD Among Survivors of Breast or Colorectal Cancer","EVALUATE","Inclusion criteria:\n\n* Signed Informed consent form\n* Age ≥ 18 years\n* Diagnosis of BC or CRC at least 5 years but no more than 10 years before enrollment, and no recurrence or new cancer diagnoses during this time period (except for superficial non-melanoma skin cancer or superficial bladder cancer or cancer in-situ). Patients who received\u002Fare still receiving adjuvant therapy may be included. Time period is calculated from date of first histological diagnosis of cancer.\n\nExclusion criteria:\n\n* Known or suspected chronic hepatic disease\n* Pregnancy, or suspected pregnancy (as liver stiffness and fat content are often elevated but reverse after childbirth)\n* For the MRI sub-study: Contraindication to MRI, including: claustrophobia and presence of metal implants or devices or foreign metal objects in\u002Fon the body, such as pacemakers, defibrillators, prosthetic cardiac valves, cochlear implants, metal clips e.g., vascular clips, spinal cord stimulators or deep brain stimulators, shrapnel or bullet fragments, metal in the eyes, orthopedic hardware and piercings that cannot be easily removed.","ALL",{"count":132,"type":20},"A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly. Examples of metabolic issues include obesity, diabetes, or high blood pressure\n\nMASLD -Metabolic-associated steatotic liver disease - also known as non-alcoholic fatty liver disease, is a condition where fat builds up in the liver due to metabolic issues. Excess liver fat can cause inflammation, scaring, also known as fibrosis, and over time, lead to liver failure.\n\nMASLD can have different severities. Non-fibrotic MASLD is when there is a small amount of fat in the liver and usually does not cause major problems. However, it can get worse over time and can develop into fibrotic MASLD.\n\nMASLD is very common, about one-third of the world's population is affected. In Switzerland, it is predicted that one-quarter of the Swiss population is affected by it. MASLD can affect anyone who has any metabolic issues, however it seems like some medications, such as cancer treatments, could play a role in MASLD development.\n\nStudying MASLD is important because it is very common. Learning more about it can help doctors find better ways to diagnose and treat the condition.\n\nFurthermore, it is important to find out who would be more likely to develop MASLD. People who are more likely could maybe do some regular testing to diagnose it early and start treatment before it is worsening. Early diagnosis is important since liver damage can be reversed with lifestyle changes, diet or medication.\n\nCancer survivors are at a higher risk of developing MASLD due to changes in their metabolism, lifestyle as well as side effects of cancer treatments. However, MASLD is often underdiagnosed in cancer survivors, even though it can increase the risk of future health complications.\n\nCurrently, liver biopsy is the standard method of diagnosing MASLD, as it provides the most accurate results. However, liver biopsy is uncomfortable and carries risks like pain and infections.\n\nNewer non-invasive technologies, such as ultrasound-based vibration-controlled transient elastography (VCTE, also known as FibroScan®) and Magnetic Resonance Imaging (MRI), show promise in detecting liver fibrosis earlier and more safely. However, they are not yet widely used because they are not as precise as biopsy at detecting liver inflammation.\n\nEVALUATE is an observational study performed by the Department of Clinical Research at the University of Bern. In collaboration with the Department of Hepatology, Inselspital, University Hospital of Bern and the Department of Radiology, University Cancer Centre Inselspital.\n\nEVALUATE will use two of the newer, less painful methods - VCTE and MRI to check for signs of fibrotic MASLD. Combined with a blood test, a score can be calculated to see if someone is at high-risk for advanced MASLD.\n\nIn the case that the results from the main study are uncertain, the participant will be asked to participate in an MRI sub study.\n\nThis study will help improve ways to check for liver disease in cancer survivors, leading to early detection and quicker treatment. Eventually the information of this study could help create better guidelines and improve care for cancer survivors at risk of liver problems.",[26,329,330],"Colorectal (Colon or Rectal) Cancer Survivors","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)",[332,333,334,335,336],"MASLD","Cancer survivorship","Survivorship care","Non-invasive imaging","Liver fibrosis screening","2025-12-01",{"date":339,"type":31},"2025-12-12",{"date":341,"type":31},"2025-11-14",{"date":343,"type":20},"2027-11-30",{"name":345,"class":38},"University of Bern",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":79,"sex":325,"minAge":16,"maxAge":4,"enrollmentInfo":353,"targetDuration":355,"studyType":84,"phases":4,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":70},"100609461","ucf-mammochat-image-repository-100609461","NCT07214883","UCF MammoChat: Image Repository","UCF MammoChat: An AI-Driven Platform for Personalized Breast Cancer Patient Support -Image Repository","Inclusion Criteria:\n\n* Adults, ages 18 and older\n* Had a radiographic breast cancer imaging test, either for screening or diagnosis of breast cancer, with either positive or negative results performed in a US institution.\n* Have an email account with access to a reliable internet connection or smartphone\n* Pregnant women may choose to participate.\n\nExclusion Criteria:\n\n* Minors , ages under 18\n* Prisoners\n* Adults who are unable to provide consent.",{"count":354,"type":20},20000,"1 Year","This study aims to develop AI models to better read diagnostic mammograms for various populations and types of breast cancer, using the images that participants donate and their responses from study questionnaire to improve patient outcomes. This study also aims to provide mammography images to participants.",[218,358,359,26,360,361],"Breast Cancer Awareness","Breast Cancer Detection","Breast Cancer Female","Breast Cancer Diagnosis",[218,363,364],"Artificial Intelligence","AI","2025-10-08",{"date":367,"type":31},"2025-10-09",{"date":369,"type":31},"2025-09-03",{"date":371,"type":20},"2026-06-30",{"name":373,"class":38},"University of Central Florida",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":15,"minAge":269,"maxAge":81,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":70},"100504425","rowing-following-breast-cancer-chemotherapy-100504425","NCT05848141","Rowing Following Breast Cancer Chemotherapy","Indoor Rowing as a Novel Exercise Therapy for Cardiovascular Rehabilitation in Middle-Aged and Older Breast Cancer Survivors Following Chemotherapy","Inclusion Criteria:\n\n* diagnosis of primary invasive non-metastatic breast cancer, stages I-III\n* female based on biological sex\n* 40 to 80 years of age\n* completed breast cancer treatment 6 to 24 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4\u002F6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed within 6 months prior to study enrollment and during study participation\n* absence of contraindications to exercise or study participation\n* study clinician approval\n\nExclusion Criteria:\n\n* do not meet inclusion criteria\n* receiving or scheduled to receive treatment for breast cancer (i.e., chemotherapy, surgery, or radiation) during study participation is not allowed. Adjuvant endocrine therapy, CDK4\u002F6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy and bisphosphonates are allowed during study participation\n* lymphedema stage ≥ 2 prior to study enrolment\n* any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)\n* current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)\n* consistent participation in ≥150 min\u002Fweek of moderate-intensity rowing exercise training in previous 6 months",{"count":299,"type":20},[23],"There are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect of a novel exercise intervention on cardiovascular rehabilitation in breast cancer survivors.",[26],"2025-08-14",{"date":387,"type":31},"2025-08-17",{"date":389,"type":31},"2024-02-26",{"date":391,"type":20},"2026-05-31",{"name":393,"class":38},"University of Florida",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":165,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":70},"100596476","concurrent-exercise-in-combination-with-music-listening-in-female-breast-cancer-survivors-100596476","NCT07045961","Concurrent Exercise in Combination With Music Listening in Female Breast Cancer Survivors","Inclusion Criteria:\n\n* Women aged between 18 and 75 years with a prior diagnosis of stage 0-III breast cancer.\n* Women currently in the survivorship phase of the disease, regardless of the type of medical or surgical treatment received.\n* A minimum of six months must have elapsed since the completion of primary treatment.\n\nExclusion Criteria:\n\n* History of lymphedema secondary to axillary surgery.\n* Inability to provide informed consent for participation in the study.\n* Prior diagnosis of hearing impairments that hinder or prevent music listening, such as partial or total deafness.\n* Prior diagnosis of any central or peripheral neurological condition.\n* Presence of comorbidities or conditions that contraindicate participation in a physical exercise program.\n\n  * A preliminary screening of participants will be conducted based on the recommendations of the National Comprehensive Cancer Network (NCCN), considering the risk of potential exercise-induced adverse effects.",{"count":401,"type":20},42,[23],"This clinical trial aims to compare the effects of a concurrent physical exercise program (aerobic and resistance training) combined with music medicine versus exercise alone on self-perception (self-esteem and body image), physical condition (strength, fatigue, cardiovascular endurance) and general well-being (quality of life and sleep quality) in female breast cancer survivors.\n\nThe main research question is:\n\n\\- Is a program that combines physical exercise and music therapy more effective than physical exercise alone in improving self-perception, physical condition, and general well-being in breast cancer survivors?\n\nParticipants will be randomly assigned to one of two groups:\n\n* One group will receive concurrent physical exercise combined with music therapy.\n* The other group will receive the same exercise program without music therapy. Assessments will be conducted at three time points: before the intervention, immediately after the intervention, and 6 months post-intervention.",[26],[406,407,408,409],"Breast cancer survivors","Concurrent exercise","Music medicine","Randomized controlled trial","2025-06-23",{"date":412,"type":31},"2025-07-01",{"date":414,"type":20},"2025-10",{"date":416,"type":20},"2026-07",{"name":418,"class":38},"Ana Trigueros Murillo",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":15,"minAge":426,"maxAge":80,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":70},"100468964","the-effect-of-myofascial-chain-release-techniques-on-shoulder-joint-range-of-motion-in-breast-cancer-survivors-100468964","NCT05386628","The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion in Breast Cancer Survivors","The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion Following Mastectomy Surgery in Breast Cancer Survivors","Inclusion Criteria:\n\n* Women between the ages of 30-60\n* Having breast surgery within 2 years\n* Not have received conservative treatment for shoulder rehabilitation in the last 6 months\n* Having limitation of movement of the shoulder joint due to breast surgery\n\nExclusion Criteria:\n\n* Not having agreed to participate in the study\n* Having undergone radical mastectomy surgery\n* Having connective tissue disease\n* Presence of brachial plexus paresis\u002Fplegia\n* Presence of radiogenic fibrosis\n* Presence of additional orthopedic (scoliosis, etc.), neurological (multiple sclerosis, stroke, etc.) and rheumatological diseases (ankylosing spondylitis, rheumatoid arthritis, etc.) that will affect upper extremity functions\n* Presence of active metastases\n* Having undergone reconstruction surgery\n* Continuation of radiotherapy (must have ended at least 3 months ago) or chemotherapy applications\n* Having had a bilateral mastectomy\n* To develop lymphedema in the arm-trunk\n* Use of muscle relaxants\n* Patients with severe chemotherapy side effects (hyperesthesia, nausea, skin changes, weakness, etc.)","30 Years",{"count":428,"type":20},48,[23],"In breast cancer patients, limitation of shoulder joint movement occurs following mastectomy surgery. Studies have reported that damage to the fascia on the pectoralis major muscle during mastectomy surgery contributes to the development of the limitation. The aim of this study is to investigate the effect of release techniques applied to the fascia on the pectoralis major muscle and the fascial chain on the incerasing of shoulder joint range of motion.",[26],[247,433,434],"range of motion","lymphatic drainage","2024-07-12",{"date":437,"type":31},"2024-07-15",{"date":439,"type":31},"2022-08-15",{"date":441,"type":20},"2025-07-15",{"name":443,"class":38},"Istanbul Medeniyet University"]